Journal list Promote Sponsor
verified SJR 0,651 · Q2 • database Scopus / SJR & Web of Science & DOAJ indexed
New Microbes and New Infections
United Kingdom · Elsevier Ltd
workspace_premium Q2 — Microbiology verified Plan S Compliant visibility_off Single blind Peer Review lock_open Open Access · DOAJ

New Microbes and New Infections

New Microbes and New Infections is a journal indexed in SJR in Microbiology and Infectious Diseases with an H index of 47. It is an CC BY Journal with a Single blind Peer Review review system, and It has a price of 1170 €. The scope of the journal is focused on Infectious Diseases. It has an SJR impact factor of 0,651 and it has a best quartile of Q2. It is published in English. It has an SJR impact factor of 0,651.

Publisher: Elsevier Ltd
Category: Microbiology
Indexation: verifiedScopus / SJR verifiedWeb of Science verifiedDOAJ
open_in_new Portal NPD menu_book Author guidelines
schedule CountryOfPapers database fields
SJR Impact Factor trending_up
0,651 Q2
H-index 47
Acceptance rate pie_chart
35%
Source Acceptance_Rate
Time to publication hourglass_top
8 weeks
Field Average_time_publication_weeks
Publication cost (APC) payments
1.170 € Open Access
Non-OA path NPD

Metrics

Scimago and CountryOfPapers database fields

Scopus / SJR Web of Science DOAJ

SJR Impact

0,651

H-index

47

Docs (year)

350

Docs 3y

349

Total refs

3164

Cites 3y

742

Citable 3y

185

Cites/Doc 2y

2

Ref/Doc

9.04

Immediate OA

1170 €

Embargoed OA

NPD

Non OA / Submission

- €

shield Researcher voice

Name good journals. Call out predatory ones.

Share what peer review, fees, and timelines were really like. Praise fair editors. Flag APC traps, fake metrics, or spam solicitations — with facts from your submission.

Fair & fast peer review Clear APC / no surprise fees Suspected predatory Fake impact claims
rate_review Write an honest review

Researcher reviews

sentiment_dissatisfied No reviews yet — be the first to share an honest experience.
User
* Only to validate authenticity — identity is not shown publicly.

FAQs